These data suggest that despite the multiple mechanisms by which ER+/HER2− breast cancer cells acquire resistance to CDK4/6 inhibition, upregulation of PI3K/mTOR signaling appears to be common, and as such may be an attractive target for reversing resistance. The gene discussed is CDK4; the disease is breast carcinoma.